Online inquiry

IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11246MR)

This product GTTS-WQ11246MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11246MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6120MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ11956MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ6972MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ7507MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ7364MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ12752MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ14168MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ10791MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW